271 related articles for article (PubMed ID: 21915801)
41. Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer.
Laheurte C; Thiery-Vuillemin A; Calcagno F; Legros A; Simonin H; Boullerot L; Jacquin M; Nguyen T; Mouillet G; Borg C; Adotévi O
Int J Cancer; 2020 Aug; 147(4):1199-1205. PubMed ID: 31749145
[TBL] [Abstract][Full Text] [Related]
42. Nodal status in luminal A invasive breast cancer: relationships with cytotoxic CD8 + and regulatory FOXP3 + cells tumor-associated infiltrate and other prognostic factors.
Glajcar A; Łazarczyk A; Tyrak KE; Hodorowicz-Zaniewska D; Streb J; Okoń K; Szpor J
Virchows Arch; 2021 Nov; 479(5):871-882. PubMed ID: 34117905
[TBL] [Abstract][Full Text] [Related]
43. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels.
Zhao J; Cao Y; Lei Z; Yang Z; Zhang B; Huang B
Cancer Res; 2010 Jun; 70(12):4850-8. PubMed ID: 20501849
[TBL] [Abstract][Full Text] [Related]
44. Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment.
Muthu Raja KR; Kubiczkova L; Rihova L; Piskacek M; Vsianska P; Hezova R; Pour L; Hajek R
PLoS One; 2012; 7(11):e49446. PubMed ID: 23152910
[TBL] [Abstract][Full Text] [Related]
45. Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells.
Tiriveedhi V; Fleming TP; Goedegebuure PS; Naughton M; Ma C; Lockhart C; Gao F; Gillanders WE; Mohanakumar T
Breast Cancer Res Treat; 2013 Feb; 138(1):109-18. PubMed ID: 22678162
[TBL] [Abstract][Full Text] [Related]
46. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
Löhr M; Freitag B; Technau A; Krauss J; Monoranu CM; Rachor J; Lutz MB; Hagemann C; Kessler AF; Linsenmann T; Wölfl M; Ernestus RI; Engelhardt S; Gelbrich G; Schlegel PG; Eyrich M
Cancer Immunol Immunother; 2018 Oct; 67(10):1545-1558. PubMed ID: 30054667
[TBL] [Abstract][Full Text] [Related]
47. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.
Muthu Raja KR; Rihova L; Zahradova L; Klincova M; Penka M; Hajek R
PLoS One; 2012; 7(10):e47077. PubMed ID: 23071717
[TBL] [Abstract][Full Text] [Related]
48. Selective Activation of Tumor Necrosis Factor Receptor II Induces Antiinflammatory Responses and Alleviates Experimental Arthritis.
Fischer R; Proske M; Duffey M; Stangl H; Martinez GF; Peters N; Kraske A; Straub RH; Bethea JR; Kontermann RE; Pfizenmaier K
Arthritis Rheumatol; 2018 May; 70(5):722-735. PubMed ID: 29342501
[TBL] [Abstract][Full Text] [Related]
49. Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer.
Scurr M; Pembroke T; Bloom A; Roberts D; Thomson A; Smart K; Bridgeman H; Adams R; Brewster A; Jones R; Gwynne S; Blount D; Harrop R; Hills R; Gallimore A; Godkin A
Clin Cancer Res; 2017 Nov; 23(22):6771-6780. PubMed ID: 28855352
[No Abstract] [Full Text] [Related]
50. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.
Rossmann E; Österborg A; Löfvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schröder A; Mellstedt H
Hum Vaccin Immunother; 2014; 10(11):3394-408. PubMed ID: 25483677
[TBL] [Abstract][Full Text] [Related]
51. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.
Hermans IF; Chong TW; Palmowski MJ; Harris AL; Cerundolo V
Cancer Res; 2003 Dec; 63(23):8408-13. PubMed ID: 14679003
[TBL] [Abstract][Full Text] [Related]
52. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
[TBL] [Abstract][Full Text] [Related]
53. Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.
Klein O; Davis ID; McArthur GA; Chen L; Haydon A; Parente P; Dimopoulos N; Jackson H; Xiao K; Maraskovsky E; Hopkins W; Stan R; Chen W; Cebon J
Cancer Immunol Immunother; 2015 Apr; 64(4):507-18. PubMed ID: 25662405
[TBL] [Abstract][Full Text] [Related]
54. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
[TBL] [Abstract][Full Text] [Related]
55. Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma.
Burton JH; Mitchell L; Thamm DH; Dow SW; Biller BJ
J Vet Intern Med; 2011; 25(4):920-6. PubMed ID: 21736624
[TBL] [Abstract][Full Text] [Related]
56. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases.
Katz SC; Bamboat ZM; Maker AV; Shia J; Pillarisetty VG; Yopp AC; Hedvat CV; Gonen M; Jarnagin WR; Fong Y; D'Angelica MI; DeMatteo RP
Ann Surg Oncol; 2013 Mar; 20(3):946-55. PubMed ID: 23010736
[TBL] [Abstract][Full Text] [Related]
57. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Park JH; Lee JL
Cancer Chemother Pharmacol; 2015 Feb; 75(2):247-54. PubMed ID: 25428517
[TBL] [Abstract][Full Text] [Related]
58. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.
Orecchioni S; Talarico G; Labanca V; Calleri A; Mancuso P; Bertolini F
Br J Cancer; 2018 May; 118(10):1329-1336. PubMed ID: 29695766
[TBL] [Abstract][Full Text] [Related]
59. Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target.
Hashemi V; Maleki LA; Esmaily M; Masjedi A; Ghalamfarsa G; Namdar A; Yousefi M; Yousefi B; Jadidi-Niaragh F
Int Immunopharmacol; 2020 Jan; 78():106087. PubMed ID: 31841758
[TBL] [Abstract][Full Text] [Related]
60. Increased sensitivity of CD4+ T-effector cells to CD4+CD25+ Treg suppression compensates for reduced Treg number in asymptomatic HIV-1 infection.
Thorborn G; Pomeroy L; Isohanni H; Perry M; Peters B; Vyakarnam A
PLoS One; 2010 Feb; 5(2):e9254. PubMed ID: 20174666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
